KR102592304B1 - 신규 세포 투과성 펩타이드 및 이의 용도 - Google Patents

신규 세포 투과성 펩타이드 및 이의 용도 Download PDF

Info

Publication number
KR102592304B1
KR102592304B1 KR1020220090172A KR20220090172A KR102592304B1 KR 102592304 B1 KR102592304 B1 KR 102592304B1 KR 1020220090172 A KR1020220090172 A KR 1020220090172A KR 20220090172 A KR20220090172 A KR 20220090172A KR 102592304 B1 KR102592304 B1 KR 102592304B1
Authority
KR
South Korea
Prior art keywords
peptide
endoplasmic reticulum
seq
cell
delivery
Prior art date
Application number
KR1020220090172A
Other languages
English (en)
Korean (ko)
Other versions
KR20230016157A (ko
Inventor
조인호
박정현
신재민
박혜진
맹재열
김민석
장지연
장재근
Original Assignee
주식회사 에이조스바이오
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 에이조스바이오, 이화여자대학교 산학협력단 filed Critical 주식회사 에이조스바이오
Publication of KR20230016157A publication Critical patent/KR20230016157A/ko
Application granted granted Critical
Publication of KR102592304B1 publication Critical patent/KR102592304B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
KR1020220090172A 2021-07-22 2022-07-21 신규 세포 투과성 펩타이드 및 이의 용도 KR102592304B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210096640 2021-07-22
KR20210096640 2021-07-22

Publications (2)

Publication Number Publication Date
KR20230016157A KR20230016157A (ko) 2023-02-01
KR102592304B1 true KR102592304B1 (ko) 2023-10-23

Family

ID=84979281

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020220090172A KR102592304B1 (ko) 2021-07-22 2022-07-21 신규 세포 투과성 펩타이드 및 이의 용도

Country Status (2)

Country Link
KR (1) KR102592304B1 (fr)
WO (1) WO2023003380A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5854283B2 (ja) * 2010-06-04 2016-02-09 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
JP6077858B2 (ja) * 2011-01-07 2017-02-08 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
CA2834577A1 (fr) * 2011-05-23 2012-11-29 Phylogica Limited Procede de determination, d'identification ou d'isolement de peptides penetrant dans des cellules
EP3825327A1 (fr) * 2014-03-11 2021-05-26 Molecular Templates, Inc. Protéines comportant des régions de liaison, des régions effectrices à sous-motifs a de shiga-toxine et des motifs de signal de localisation du réticulum endoplasmique carboxy-terminaux
CA3089279A1 (fr) * 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Modules peptidiques agrafes permeables aux cellules pour administration cellulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
일본특허등록공보 특개평6077858호 (2017.01.20.)*

Also Published As

Publication number Publication date
WO2023003380A1 (fr) 2023-01-26
KR20230016157A (ko) 2023-02-01

Similar Documents

Publication Publication Date Title
US20220175933A1 (en) Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma
ES2407994T3 (es) Utilización de ligando Flt3 para reforzar las respuestas inmunológicas en la inmunización con ARN
US11338027B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
CA2542269C (fr) Molecules de fusion comprenant des antigenes et des zones cytoplasmiques d'une molecule cmh i ou ii
US7700109B2 (en) Biomolecule transduction motif Mph-1-BTM and the use thereof
PT1408114E (pt) Moléculas modulares de transportes de antigénios ( moléculas mat ) para modulação de respostas imunitárias, correspondentes construções, processos e utilizações.
WO2011101332A1 (fr) Compositions basées sur le domaine extracellulaire a de fibronectine pour le traitement d'un mélanome
US7354737B2 (en) Biomolecule transduction motif Sim-2-BTM and the use thereof
EP1408048A1 (fr) Vaccins avec pouvoir immunogène accru et leur procédé de préparation
KR102592304B1 (ko) 신규 세포 투과성 펩타이드 및 이의 용도
Shibagaki et al. Novel immunotherapeutic approaches to skin cancer treatments using protein transduction technology
Udhayakumar Development and validation of synthetic-virus like vaccines
under Rule wo 2011/101332 Ai II II II Iiii I1 1 11III III II
Kaneda et al. Toshihiro Nakajima** Division of Gene Therapy Science, Graduate School of Medicine Osaka University, Suita, Osaka 565-0871, Japan* GenomIdea Inc., 7-7-15 Saito-Asagi, Ibaragi
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant